CHMP recommends eight new drugs for approval – one cancer drug rejected

The expert panel at the EMA recommended eight new drugs for approval at its meeting in June, and backed extensions of therapeutic indication for six existing treatments.


European practitioners will gain new methods for treatment after the June meeting of the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) where the panel recommended several novel drug candidates and new indications for existing drugs.

Celgene's gene therapy Abecma (idecabtagene vicleucel) was for example nominated for conditional marketing authorization as a fourth-line therapy for bone marrow cancer. CHMP also had a positive view of Biomarin's Voxzogo (vosoritid) for the day-to-day treatment of children with achondroplasia. This drug might eventually challenge Transcon CNP, which is produced by Danish biotech firm Ascendis, if the latter reaches the market.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs